Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

DOI Full Paper Access

182

Citations

24

References

2018

Year

Paola Fioretto, Stefano Del Prato, John B. Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C. David Sjöström, Peter Sartipy

Diabetes Obesity and Metabolism

Abstract

The findings of this study (NCT02413398, clinicaltrials.gov) support the positive benefit/risk profile of dapagliflozin for the treatment of patients with T2D and CKD 3A.

References

	Year	Citations

Page 1